Comparing stem cell transplant vs standard therapy for sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study compares two treatment approaches for children with sickle cell anemia: a stem cell transplant from a matched family donor versus continuing regular disease-modifying medicines. It aims to see which treatment works better over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 3 and 20 years old (up to 20 years and 11 months).
- Your child must have sickle cell anemia (HbSS or HbS/β0 thalassemia).
- Your child is either: considering a stem cell transplant from a matched family donor (like a sibling), or continuing regular sickle cell treatments like hydroxyurea.
- You and your child agree to participate and complete checkups over 3 years.
- Your child cannot be in another research study that might conflict with this one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood cells in people with sickle cell disease and is done to better understand the disease. If you join, researchers will likely take a blood sample to see how your cells are working.
This trial compares a new gene therapy to the standard care for people with severe sickle cell disease. It aims to see if the gene therapy is better at reducing painful crises and complications.
This Phase 2 study tests a type of stem cell transplant that uses donor immune cells that have been specially “tweaked” to help treat sickle cell disease. It may help prevent serious sickle cell complications, but it requires careful matching and screening of organs and pregnancy status.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
This trial tests whether a stem cell transplant from a partially gene-matched family member can cure severe sickle cell disease in children and young adults. The transplant uses a new approach that may work even when a perfectly matched sibling isn't available, and it might help patients whose sickle cell is causing serious complications like strokes, organ damage, or frequent pain crises.
This trial tests whether a half-matched (haploidentical) blood stem cell transplant can treat adults with severe sickle cell disease. It may help reduce serious complications and improve survival, but it requires a fit health status and specific donor and medical conditions.
Hear when a new Sickle Cell Disease (SCD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.